Connect Biopharma Holdings Limited (CNTB)

NGM – Цена в реальном времени. Валюта: USD

2.68

+0.34 (14.53%)

При закрытии: May 12, 2026, 4:00 PM EDT

2.61

-0.07 (-2.57%)

До открытия: May 13, 2026, 8:34 AM EDT

12.05.2026

Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference

SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026 at 9:30 a.m. ET.

12.05.2026

Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update

– Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD continuing as planned based on independent DMC review of pre-specified interim analysis –

29.04.2026

Connect Biopharma: New Market Opportunity In The Emergency Setting

Connect Biopharma Holdings is rated a risky Buy, with high upside potential hinging on mid-2026 Phase 2 trial results for rademikibart. Rademikibart has shown superior efficacy and safety to Dupixent in China Phase 3 trials, with commercialization led by Simcere and low-double-digit royalties to CNTB. CNTB is targeting the emergency asthma and COPD settings in the US, a market with no approved biologics, and expects pivotal Phase 2 data in mid-2026.

23.04.2026

Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis

SAN DIEGO, April 23, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that the independent Data Monitoring Committee (DMC) overseeing its Phase 2 Seabreeze STAT asthma and COPD trials evaluating rademikibart, the Company's next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody, has completed its review of the pre-specified interim analysis of efficacy with no recommendation for change in the sample size. “Based on the DMC's review of interim efficacy results from our ongoing Seabreeze STAT acute asthma and COPD studies, enrollment will continue as planned with no change in sample size,” said Barry Quart, Pharm.D.

31.03.2026

Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

– Released positive topline data from Phase 1 study of IV rademikibart in patients with asthma or COPD – – Results from Phase 3 study of rademikibart in moderate-to-severe AD presented in late-breaking research session at AAD – – Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both studies mid-2026 – – Entered into a securities purchase agreement for $20.2 million equity financing extending our cash runway into second half of 2027 – SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today reported financial results for the three and twelve months ended December 31, 2025, and provided a business update. “2025 was an eventful year for our lead drug candidate, rademikibart, with the initiation of our Phase 2 Seabreeze STAT studies in acute asthma and chronic obstructive pulmonary disease (COPD),” said Barry Quart, Pharm.D.

30.03.2026

Connect Biopharma Holdings Limited (CNTB) Discusses Phase 3 Atopic Dermatitis Study Results and Updates on Rademikibart Development Transcript

30.03.2026

Connect Biopharma Announces $20.2 Million Private Placement Financing

Funding from new and existing investors extends anticipated cash runway into the second half of 2027 SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma,” “Connect” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell 6,130,000 shares of its ordinary shares in a private placement at a price of $3.25 per share with respect to any purchaser that is not owned or controlled by an individual who is an officer, director, employee or consultant of the Company. Connect anticipates the gross proceeds from the private placement will be approximately $20.2 million, before deducting placement agent fees and other offering expenses.

Видео

No Data

There is no data to display

Пресс-релизы

12.05.2026

Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update

– Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD continuing as planned based on independent DMC review of pre-specified interim analysis –

23.04.2026

Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis

31.03.2026

Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

30.03.2026

Connect Biopharma Holdings Limited (CNTB)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Connect Biopharma Holdings Limited (CNTB)

Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference

Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update

Connect Biopharma: New Market Opportunity In The Emergency Setting

Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis

Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

Connect Biopharma Holdings Limited (CNTB) Discusses Phase 3 Atopic Dermatitis Study Results and Updates on Rademikibart Development Transcript

Connect Biopharma Announces $20.2 Million Private Placement Financing

Видео

No Data

Пресс-релизы

Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update

Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis

Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

Connect Biopharma Announces $20.2 Million Private Placement Financing

Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference

Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update

Connect Biopharma: New Market Opportunity In The Emergency Setting

Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis

Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

Connect Biopharma Holdings Limited (CNTB) Discusses Phase 3 Atopic Dermatitis Study Results and Updates on Rademikibart Development Transcript

Connect Biopharma Announces $20.2 Million Private Placement Financing

Видео

No Data

Пресс-релизы

Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update

Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis

Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

Connect Biopharma Announces $20.2 Million Private Placement Financing

Search stocks

Connect Biopharma Holdings Limited (CNTB)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Connect Biopharma Holdings Limited (CNTB)

Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference

Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update

Connect Biopharma: New Market Opportunity In The Emergency Setting

Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis

Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

Connect Biopharma Holdings Limited (CNTB) Discusses Phase 3 Atopic Dermatitis Study Results and Updates on Rademikibart Development Transcript

Connect Biopharma Announces $20.2 Million Private Placement Financing

Видео

No Data

Пресс-релизы

Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update

Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis

Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

Connect Biopharma Announces $20.2 Million Private Placement Financing

Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference

Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update

Connect Biopharma: New Market Opportunity In The Emergency Setting

Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis

Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

Connect Biopharma Holdings Limited (CNTB) Discusses Phase 3 Atopic Dermatitis Study Results and Updates on Rademikibart Development Transcript

Connect Biopharma Announces $20.2 Million Private Placement Financing

Видео

No Data

Пресс-релизы

Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update

Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis

Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

Connect Biopharma Announces $20.2 Million Private Placement Financing